The proposed new warning would advise against taking more than the recommended dose or taking PPA-containing drugs with others also containing PPA, phenylephrine, pseudoephedrine, or ephedrine. Labels for PPA weight control drugs would state they are to be taken only by those over 18 years old and that higher doses will not cause additional weight loss. The agency also is proposing that OTC drugs list sodium content and is working with pharmaceutical organizations to develop voluntary sodium labeling for prescription drugs. Labels would list total sodium content if it exceeds 5 mg and a statement would be added to the warning section if sodium exceeds 140 mg.
FDA proposes additional warning on some OTC drug labels
The Food & Drug Administration wants an additional warning on over-the-counter (OTC) drugs containing phenylpropanolamine (PPA), a common ingredient in weight control, cough-cold, allergy and nasal decongestant drugs.
Jul 31, 1996
Recommended
Recommended
Machinery Basics
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? <i>Packaging World</i> editors explore the survey responses from 118 brand owners, CPG, and FMCG <i>Packaging World</i> readers for its new Annual Outlook Report.
Download
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
